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Background:  Although there is a high prevalence of abnormal glucose metabolism in patients with coronary artery disease (CAD), especially acute 
coronary syndrome (ACS), only HbA1C and/or fasting glucose which relatively miss daily hyperglycemic excursions were evaluated in previous studies 
associated with CAD. 1,5-anhdroglucitol (1,5-AG) has been used as an appropriate marker to detect for postprandial hyperglycemia. Moreover, 
measurement of 1,5-AG is not affected by meals or exercise. However, the association between 1,5-AG and CAD has not been clarified.
Methods: Of 204 consecutive patients who underwent percutaneous coronary intervention (PCI) in our hospital and had no history of PCI or bypass 
surgery, 159 patients without a previous diagnosis of diabetes were examined. Moreover, we excluded 51 patients with A1C levels >7.0% and/or 
glucose levels >126mg/dl. Finally, 108 Patients without diabetes mellitus were examined glucose metabolism and other risk factors in fasting state 
after admission for PCI.
Results:  Levels of A1C, homeostasis model assessment ratio, lipid profile without high density lipoprotein cholesterol (HDL-C), and other risk 
factors were not significant difference between the patients with ACS (N=63) and stable effort angina pectoris (N=45). 1,5-AG was significantly lower 
(19.4±6.3μg/ml vs. 22.5±8.4μg/ml, P=0.035) and fasting glucose was higher (105±12mg/dl vs. 99±8mg/dl, P=0.004) in patients with ACS than 
those with effort angina pectoris. We also found that HDL-C correlated significantly better with 1,5-AG (r=0.33, P<0.001) than homeostasis model 
assessment ratio (r=-0.2, P=0.04), fasting glucose (r=-0.08, P=NS), and A1C (r=-0.06, P=NS).
Conclusions: Serum levels of 1,5-AG were significantly lower in patients with ACS, among non-diabetic patients. Moreover, 1,5-AG was also 
significantly correlated with HDL-C which possesses multiple antiatherogenic activities. This indicates that 1,5-AG would be an additional useful 
marker used in conjunction with other conventional risk factors to detect and evaluate glycemic risk for patients with ACS.
